Top Overvalued Biotechnology industry Stocks 2026

MeiraGTx Holdings (MGTX) is the most overvalued stock in the Biotechnology industry with an estimated 20.6% downside, followed by EyePoint Pharmaceuticals, (EYPT) at 19.0%, KalVista Pharmaceuticals, (KALV) at 19.0%, and Veracyte, (VCYT) at 18.9%.

Updated todayBased on intrinsic value modelsIndustry: Biotechnology

Page snapshot: 14 July 2026, 4:26 am

View full analysis in the screener → · All overvalued →

Before you trade on valuation alone

Cross-check fair value with fundamentals, liquidity, and your own goals—this table is a screen, not advice.

Check if a stock is overvalued See intrinsic value →

Biotechnology Industry Valuation Insights (Updated Today)

The Biotechnology industry currently shows an average upside of 18.2% on this snapshot.
Top name MeiraGTx Holdings plc (MGTX) trades at roughly a 20.6% discount to modeled intrinsic value—rankings move with prices and inputs.
This industry's average upside is below our broad overvalued benchmark (~21.7%).

Overvalued Biotechnology Stocks by Market Cap

Large cap (top 5)

1.Royalty Pharma plc · RPRX13.5%$24.27B

Mid cap (top 5)

1.Veracyte, Inc. · VCYT18.9%$4.55B
2.Vericel Corporation · VCEL18.5%$2.4B

Small cap (top 5)

1.MeiraGTx Holdings plc · MGTX20.6%$1.24B
2.EyePoint Pharmaceuticals, Inc. · EYPT19.0%$1.23B
3.KalVista Pharmaceuticals, Inc. · KALV19.0%$1.44B

What Are Overvalued Biotechnology Stocks?

Overvalued biotechnology stocks are names where price sits above modeled fair (intrinsic) value—often expressed as positive headline downside versus the current quote.

This is not a sell list. Validate each symbol on its company page before you act.

How We Identify Overvalued Biotechnology Stocks

We pull an industry-filtered overvalued snapshot (price, intrinsic value, downside, cap, sector, country) and rank by headline downside. You can sort and search in the table above.

Rankings can shift intraday as prices and model inputs move. Use the stock screener for custom filters beyond this industry leaderboard.

FAQs

Answers about overvalued biotechnology names, intrinsic value, and how often this list refreshes.

What are overvalued biotechnology stocks?

They are Biotechnology names trading above modeled intrinsic value—shown here as downside % versus price. Models vary; use this as a screen, not advice.

How do you find overvalued biotechnology stocks?

We load overvalued names for this industry from our API, then rank and filter in the table. Sort columns and open company pages to dig deeper.

Why are biotechnology stocks overvalued?

Often sentiment, earnings, cycles, rates, or stock-specific news—not always a “misprice.” Intrinsic value is model-dependent.

Are overvalued biotechnology stocks a good investment?

Not by label alone. Discounts can reflect risk or data lag. Check fundamentals and your goals; seek professional advice if needed.

How often is this list updated?

The page rebuilds on a schedule (ISR). Live quotes can move faster—use company pages for the latest.